What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Parkinson's disease
His main research concerns Randomized controlled trial, Internal medicine, Placebo, Surgery and Disease.
His Randomized controlled trial study integrates concerns from other disciplines, such as Clinical trial, Tics, Rasagiline, Physical therapy and Tourette syndrome.
His research is interdisciplinary, bridging the disciplines of Gastroenterology and Internal medicine.
His Placebo research is multidisciplinary, incorporating elements of Anesthesia, Adverse effect, Levodopa, Randomization and Neurological disorder.
His Surgery research includes elements of Uric acid, Selegiline, Prevalence studies and Pediatrics.
His study in Disease is interdisciplinary in nature, drawing from both Cross-sectional study and Neuroscience.
His most cited work include:
- Projected number of people with parkinson disease in the most populous nations, 2005 through 2030 (1549 citations)
- Unified huntington’s disease rating scale: Reliability and consistency (1453 citations)
- Levodopa and the progression of Parkinson's disease. (1328 citations)
What are the main themes of his work throughout his whole career to date?
Karl Kieburtz spends much of his time researching Disease, Clinical trial, Internal medicine, Parkinson's disease and Placebo.
His Disease research includes themes of Psychological intervention, Neuroscience and Rating scale.
Karl Kieburtz interconnects Psychiatry, Cognition, Intensive care medicine, Alternative medicine and Physical therapy in the investigation of issues within Clinical trial.
The various areas that Karl Kieburtz examines in his Internal medicine study include Gastroenterology, Surgery and Oncology.
His studies in Parkinson's disease integrate themes in fields like Biomarker and Neuroprotection.
His research integrates issues of Tolerability, Adverse effect, Anesthesia and Randomized controlled trial in his study of Placebo.
He most often published in these fields:
- Disease (32.60%)
- Clinical trial (32.23%)
- Internal medicine (29.67%)
What were the highlights of his more recent work (between 2017-2021)?
- Parkinson's disease (27.84%)
- Disease (32.60%)
- Internal medicine (29.67%)
In recent papers he was focusing on the following fields of study:
Karl Kieburtz mainly investigates Parkinson's disease, Disease, Internal medicine, Clinical trial and Cohort.
The study incorporates disciplines such as Anesthesia, Pharmacokinetics, Cerebrospinal fluid, Neuroscience and Dopaminergic in addition to Parkinson's disease.
He has included themes like Psychological intervention, Cognition, Set and Rating scale in his Disease study.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Placebo and Oncology.
He has researched Clinical trial in several fields, including Huntington's disease, Regulatory science, Knowledge management and Intensive care medicine.
Karl Kieburtz combines subjects such as Randomized controlled trial and Vital signs with his study of Adverse effect.
Between 2017 and 2021, his most popular works were:
- The Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohort (83 citations)
- Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort (49 citations)
- Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study (37 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
Karl Kieburtz focuses on Disease, Internal medicine, Parkinson's disease, Clinical trial and Dopamine transporter.
His research investigates the connection between Disease and topics such as Cognition that intersect with problems in Progressive neurodegenerative disorder, Huntington's disease, Intensive care medicine and Chorea.
The concepts of his Internal medicine study are interwoven with issues in Dose-ranging study, Oncology and Rating scale.
His Parkinson's disease research incorporates elements of Cohort study, Rapid eye movement sleep, Dopaminergic, Tolerability and Antihistamine.
The subject of his Clinical trial research is within the realm of Bioinformatics.
Karl Kieburtz works mostly in the field of Dopamine transporter, limiting it down to topics relating to Movement disorders and, in certain cases, LRRK2 and Cross-sectional study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
